The agreement, with an effective date of June 1, 2008 provides MedAssets’s customers access to Dilon’s cornerstone product, The Dilon 6800 gamma camera.
The Dilon 6800 performs a molecular breast imaging technique called breast-specific gamma imaging, which can detect lesions independent of tissue density and discover very early stage cancers, according to Dilon.